78. Hypopituitarism Clinical trials / Disease details

Clinical trials : 492 / Drugs : 341 - (DrugBank : 47) / Drug target genes : 45 - Drug target pathways : 100

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00675506 (ClinicalTrials.gov)	July 2008	7/5/2008	Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese	Physiologic Effects of Long-Term GHRH1-44 in Abdominal Obesity	Abdominal Obesity;Growth Hormone Deficiency	Drug: Growth hormone releasing hormone (GHRH) 1-44;Drug: Placebo	Massachusetts General Hospital	National Heart, Lung, and Blood Institute (NHLBI)	Completed	18 Years	55 Years	All	60	Phase 2	United States
2	NCT00720902 (ClinicalTrials.gov)	February 2007	16/6/2008	Adult Growth Hormone Deficiency and Cardiovascular Risk	Assessment of Cardiovascular Risk Markers in GH Deficient Patients With Nonsecreting Pituitary Adenomas	Growth Hormone Deficiency	Procedure: Blood draws;Drug: Growth hormone releasing hormone (GHRH) and arginine;Procedure: Carotid ultrasound;Procedure: MRI;Procedure: Endothelial cell biopsy	Columbia University	NULL	Terminated	19 Years	65 Years	Both	8	N/A	United States
3	EUCTR2004-002125-42-IT (EUCTR)	22/09/2004	09/08/2007	EFFECT OF PROLONGED TREATMENT WITH TH9507 ON IGF-I LEVELS IN ADOLESCENTS WITH ISOLATED GH DEFICIENCY DUE TO HYPOTHALAMIC PATHOGENESIS	EFFECT OF PROLONGED TREATMENT WITH TH9507 ON IGF-I LEVELS IN ADOLESCENTS WITH ISOLATED GH DEFICIENCY DUE TO HYPOTHALAMIC PATHOGENESIS	EVALUATION OF GROWTH HORMONE RELEASE	INN or Proposed INN: Somatorelin	AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy